Cambridge Cognition Holdings ( (GB:COG) ) just unveiled an update.
Cambridge Cognition Holdings has secured a £1 million contract to provide digital cognitive assessments for a Phase 3 autoimmune disease clinical trial, marking repeat business with a major pharmaceutical company. This contract highlights the growing recognition of cognitive symptoms in autoimmune diseases and strengthens Cambridge Cognition’s position in the late-stage CNS trials market, following a recent contract for trials in adolescents with Major Depressive Disorder.
More about Cambridge Cognition Holdings
Cambridge Cognition is a brain health software group specializing in digital health products aimed at advancing brain health research and treatment. The company offers products such as CANTAB® assessments, a flexible eCOA platform, rater training services, and quality assurance tools, which collectively improve clinical trial outcomes and enhance global efficiency in healthcare and pharmaceuticals.
YTD Price Performance: -12.00%
Average Trading Volume: 30,639
Technical Sentiment Signal: Strong Buy
Current Market Cap: £13.82M
For an in-depth examination of COG stock, go to TipRanks’ Stock Analysis page.